Rick Sorensen

561 total citations · 1 hit paper
8 papers, 472 citations indexed

About

Rick Sorensen is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Rick Sorensen has authored 8 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 4 papers in Pathology and Forensic Medicine and 3 papers in Immunology. Recurrent topics in Rick Sorensen's work include Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (4 papers) and Viral-associated cancers and disorders (2 papers). Rick Sorensen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (4 papers) and Viral-associated cancers and disorders (2 papers). Rick Sorensen collaborates with scholars based in United States and Australia. Rick Sorensen's co-authors include Peter Baum, Fred Ramsdell, Michael F. Seldin, Sundaramoorthy Srinivasan, K N Clifford, Richard B. Gayle, M. Watson, G.R. Sutherland, Elizabeth Baker and Michael R. Comeau and has published in prestigious journals such as Journal of Biological Chemistry, The EMBO Journal and Blood.

In The Last Decade

Rick Sorensen

8 papers receiving 464 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34.

1994 252 citations Peter Baum, Richard B. Gayle et al. The EMBO Journal profile →

Peers

Countries citing papers authored by Rick Sorensen

Since Specialization

Citations

This map shows the geographic impact of Rick Sorensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rick Sorensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rick Sorensen more than expected).

Fields of papers citing papers by Rick Sorensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rick Sorensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rick Sorensen. The network helps show where Rick Sorensen may publish in the future.

Co-authorship network of co-authors of Rick Sorensen

This figure shows the co-authorship network connecting the top 25 collaborators of Rick Sorensen. A scholar is included among the top collaborators of Rick Sorensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rick Sorensen. Rick Sorensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors 2017 ·PLoS ONE ·(unknown), Sarah Meadows, Rick Sorensen, Zhi-Hua Cui, Kathleen S. Keegan, Robert Brockett, Guang Chen, Christophe Quéva, Li Li, Stacey Tannheimer	38
2	Evaluation of Idelalisib with B-Cell Receptor or Orthogonal Pathway Inhibitors in Diffuse Large B-Cell Lymphoma Cell Lines in Vitro and In Vivo 2016 ·Blood ·Sarah Meadows, (unknown), Rick Sorensen, Zhi-Hua Cui, Robert Brockett, Kathleen S. Keegan, Stacey Tannheimer	2
3	Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line 2015 ·Blood ·Rick Sorensen, Sarah Meadows, (unknown), Li Li, Yue Peng, Adam Kashishian, Christophe Quéva, Stacey Tannheimer	4
4	Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib 2015 ·Blood ·Sarah Meadows, Rick Sorensen, (unknown), Jia Liu, Li Li, Yue Peng, Christophe Quéva, Stacey Tannheimer	4
5	Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors 2015 ·Blood ·Stacey Tannheimer, Jia Liu, Rick Sorensen, (unknown), Sarah Meadows, Li Li, Yue Peng, Kathleen S. Keegan, Jamie Bates, Daniel B. Tumas, Christophe Quéva	4
6	Nectin-like Protein 2 Defines a Subset of T-cell Zone Dendritic Cells and Is a Ligand for Class-I-restricted T-cell-associated Molecule 2005 ·Journal of Biological Chemistry ·Laurent Galibert, Geoffrey S. Diemer, Zhi Liu, Richard S. Johnson, Jeffrey L. Smith, Thierry Walzer, Michael R. Comeau, Charles T. Rauch, Martin F. Wolfson, Rick Sorensen, Anne-Renée Van der Vuurst de Vries, Daniel Branstetter, (unknown), John Scholler, William C. Fanslow, Peter Baum, Jonathan M.J. Derry, Wei Yan	146
7	Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor. 1994 ·PubMed ·Peter Baum, Richard B. Gayle, Fred Ramsdell, Sundaramoorthy Srinivasan, Rick Sorensen, M. Watson, Michael F. Seldin, K N Clifford, K H Grabstein, Mark R. Alderson	22
8	Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. breakdown → 1994 ·The EMBO Journal ·Peter Baum, Richard B. Gayle, Fred Ramsdell, Sundaramoorthy Srinivasan, Rick Sorensen, M. Watson, Michael F. Seldin, Elizabeth Baker, G.R. Sutherland, K N Clifford	252

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact